PrimeRFP SCOUT · Federal Contract Profile

Leidos Biomedical Research (HV8BH9BPG8Y9)Federal contracts · 31 recompetes

Leidos Biomedical Research holds $2.15B in federal volume across 186 award actions, with 100% at Department of Health and Human Services (HHS). SCOUT tracks 31 incumbent recompetes — an estimated $720.3M returning to market over the next 24 months (High exposure). Primary work: Facilities Support Services; Research And Development In The (100% prime). Obligations are down 36% year over year.

$2.15B

Federal Volume

Recompetes (24mo)

HHS

Top Agency · 100% firm-wide

186

Award Actions

Choose one — this changes what we ask next

Score my firm against Leidos Biomedical Research

Email me when a Leidos Biomedical Research recompete window opens.

Data through August 2026 · refreshed monthly · window Aug 2025 – Aug 2026

What they do

Capability

Service lines

FACILITIES SUPPORT SERVICES · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)

Work mix: 100% prime · 0% sub · primary NAICS 541715 / PSC AN12 HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH

Where they win

Sole agency

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$2.1B · 100% of firm total

Recompete exposure: High · 31 in 24mo

Leidos Biomedical Research has an estimated $720.3M in contracts returning to market over the next 24 months.

Part of the LEIDOS BIOMEDICAL RESEARCH INC corporate family · 2 entities

Metrics basis: local_db

Who buys from them

Agency buyer map

1 buyers

Department of Health and Human Services (HHS)635 awards · repeat buyer · $2.1B

Recompete exposure & trajectory

Recompete exposure

High

Leidos Biomedical Research has an estimated $720.3M in contracts returning to market over the next 24 months. 12 within 6 months ($219.9M).

Soonest 12 of 31 to expire.

WEDGEWOOD EXPANSION DESIGN SUITES M & N →

PIID: 75N91021F00019 · Expires 2026-08-19

$7.8M

ENABLING NCI CLINICAL & RESEARCH DATA SHARING →

PIID: 75N91021F00013 · Expires 2026-08-31

$81.1M

FY21 CONSOLIDATED FACILITIES TASK ORDER C →

PIID: 75N91021F00006 · Expires 2026-09-04

$18.6M

ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT →

PIID: 75N91021F00017 · Expires 2026-09-15

$12.1M

DEVELOPMENT OF CANINE IMMUNOTHERAPY TARGETED AGENTS →

PIID: 75N91021F00016 · Expires 2026-09-15

$6.6M

INFRASTRUCTURE IMPROVEMENTS →

PIID: 75N91021F00018 · Expires 2026-09-24

$4.6M

RETROSPECTIVE TUMOR CHARACTERIZATION ANALYSIS (MOONSHOT) →

PIID: HHSN26100039 · Expires 2026-09-30

$21.3M

HHSN261201500003I; HHSN26100080; 400.001.0080.0001; NCI OD-FREDERICK; APPROPRIATED; 125073 BLDG. 560, ROOF EXHAUST STACKS; 9/24/2018 - 9/22/ →

PIID: 75N91018F00080 · Expires 2026-10-02

$10.0M

NIAID DIR-CLINICAL RESEARCH SUPPORT, CANCER RESEARCH TECHNOLOGY PROGRAM, BIOINFORMATICS-BIOMEDICAL INFORMATICS, AND DATA SCIENCE, GOVERNMENT →

PIID: 75N91020F00005 · Expires 2026-11-01

$37.5M

NCI-DCP-21-0103 COORDINATING CENTER FOR THE NCI CERVICAL CANCER LAST MILE INITIATIVE SELF-SAMPLING FOR HPV TESTING TO IMPROVE CERVICAL CANCE →

PIID: 75N91021F00014 · Expires 2026-12-31

$8.0M

THIS IS A CPFF TO TO REFURBISH APA BUILDINGS (1033). →

PIID: 75N91022F00030 · Expires 2027-02-05

$6.4M

FY22 - APA BUILDINGS - BUILDING 1 →

PIID: 75N91022F00027 · Expires 2027-02-05

$5.9M

Trajectory

▼ Consolidating-36% YoYFY2025 vs FY2024

'23

'24

'25

Teaming relationships

Leidos Biomedical Research teams with

MITCHELL GROUP, INC. (THE) →as prime with

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI →as prime with

AMERICAN TYPE CULTURE COLLECTION →as prime with

THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCHas prime with

FRED HUTCHINSON CANCER CENTER →as prime with

FISHER BIOSERVICES INC →as prime with

VANDERBILT UNIVERSITY →as prime with

CHILDREN'S RESEARCH INSTITUTE →as prime with

GENERAL DYNAMICS INFORMATION TECHNOLOGY, INC. →as prime with

THERMO ELECTRON NORTH AMERICA LLC →as prime with

BETH ISRAEL DEACONESS MEDICAL CENTER, INC. →as sub to

UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL →as sub to

THE LELAND STANFORD JUNIOR UNIVERSITY →as sub to

REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE →as sub to

Partners from federal subaward / teaming records (public).

“With competitive federal procurements, winning starts with strategically understanding the customer environment to the left of SAM.gov. This is what SCOUT does - a deeper and more precise understanding of what the…”

— Peter Lierni, Solutioneering

Explore another company

Don’t see your company?

Enter your company name and we'll build the page.

Query this company live in SCOUT via MCP — personalized displacement scoring, alerts, and capture workflow. Learn about SCOUT MCP →

Frequently asked questions

What federal contracts does Leidos Biomedical Research hold?

Leidos Biomedical Research (UEI HV8BH9BPG8Y9) shows $2.1B across 186 award actions in SCOUT’s public USASpending-backed profile, with Department of Health and Human Services (HHS) as the top buying agency. Totals cover federal prime awards ≥$100K in the rolling window.

How much in federal contracts does Leidos Biomedical Research have?

Leidos Biomedical Research shows $2.1B across 186 award actions. SCOUT tracks 31 incumbent recompetes ($720.3M) returning to market in the next 24 months.

Which agencies does Leidos Biomedical Research work with?

Leidos Biomedical Research’s firm-wide obligated mix is led by Department of Health and Human Services (HHS) (100%).

What is the UEI for Leidos Biomedical Research?

The Unique Entity ID (UEI) for Leidos Biomedical Research is HV8BH9BPG8Y9.

Does Leidos Biomedical Research have contracts coming up for recompete?

Yes — SCOUT tracks 31 incumbent recompetes in the next 24 months (High exposure). Open the recompete section on this page for PIID-level timing.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.